Aqilion, led by CEO Sarah Fredriksson, focuses on developing new treatments for diseases caused by chronic inflammation. In February, the company announced a major licensing deal and strategic collaboration with Merck. The deal, worth upwards of EUR 950 million, is aimed at the discovery, development and commercialisation of TAK1 protein inhibitors. The company’s Chairman, Bertil Lindmark, visited the BioStock Studio to talk about his vision for the company and ambitions for continued success.
Watch the interview with Aqilion’s Chairman Bertil Lindmark below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.